HIIFS
IMDX

Harel Insurance Investments & Financial Services’s Insight Molecular Diagnostics IMDX Stock Holding History

Harel Insurance Investments & Financial Services’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-4
Closed – – 477
2017
Q4 		$0 Hold
4
– – ﹤0.01% 492
2017
Q3 		$1K Hold
4
– – ﹤0.01% 416
2017
Q2 		$0 Hold
4
– – ﹤0.01% 436
2017
Q1 		$0 Hold
4
– – ﹤0.01% 464
2016
Q4 		$1K Hold
4
– – ﹤0.01% 363
2016
Q3 		$0 Hold
4
– – ﹤0.01% 610
2016
Q2 		$0 Hold
4
– – ﹤0.01% 697
2016
Q1 		$0 Buy
+4
New +$354 ﹤0.01% 453

Other funds holding IMDX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
DWM
Destination Wealth Management Walnut Creek, California $3.85B AUM 13% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Harel Insurance Investments & Financial Services's IMDX Position: Q1 2018 in Review

Harel Insurance Investments & Financial Services sold out of Insight Molecular Diagnostics (IMDX) in Q1 2018, closing a stake of 4 shares.

Harel Insurance Investments & Financial Services first reported a position in IMDX in Q1 2016 and held it in 8 quarters. The position peaked at $1K in Q3 2017. 39 funds tracked by Wall St. Rank hold IMDX as of Q1 2018.

  • Harel Insurance Investments & Financial Services reported no remaining Insight Molecular Diagnostics position as of Q1 2018 after selling out during the quarter.
  • Harel Insurance Investments & Financial Services sold 4 Insight Molecular Diagnostics shares in Q1 2018.
  • Harel Insurance Investments & Financial Services first reported a position in Insight Molecular Diagnostics in Q1 2016 and held it in 8 quarters.
  • Harel Insurance Investments & Financial Services's Insight Molecular Diagnostics position peaked at $1K in Q3 2017.
  • 39 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q1 2018.

Based on Harel Insurance Investments & Financial Services's 13F filing for Q1 2018, filed 30 Apr 2018.